W. Geese

T. Zander, M. Odenthal, Y. Ko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Arun Ahuja, C. Rudin, J. Wolchok, 2018, Cancer cell.

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

M. Socinski, D. Carbone, S. Peters, 2016 .

Genetic analysis implicates resistin in HIV lipodystrophy

O. Flint, M. Noor, P. Tebas, 2008, AIDS.

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Paolo A Ascierto, Ariella Sasson, Ryan Golhar, 2018, Cancer cell.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non – Small-Cell Lung Cancer : Results From the CA 209-003 Study

David C. Smith, Julie, L. Sequist, 2018 .

144TiPCheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

K. O'Byrne, S. Ramalingam, M. Hellmann, 2017 .

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

E. Felip, L. Crinò, E. Vokes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer

J. Szustakowski, S. Kirov, Han Chang, 2019, Molecular Diagnosis & Therapy.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

J. Szustakowski, P. Ascierto, F. Hirsch, 2019, Cancer cell.

Abstract 5528: Evaluation of tumor mutation burden as a biomarker for immune checkpoint inhibitor efficacy: A calibration study of whole exome sequencing with FoundationOne®

J. Szustakowski, Han Chang, K. Zerba, 2018, Clinical Research (Excluding Clinical Trials).

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2018, Clinical Trials.

Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

M. Socinski, D. Carbone, S. Peters, 2017 .

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

P. Ascierto, J. Larkin, M. Sznol, 2020, Future oncology.

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

K. Harrington, M. Monga, E. Vokes, 2016 .

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

J. Szustakowski, T. Laajala, Raghvendra Mall, 2022, bioRxiv.

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer

J. Szustakowski, S. Kirov, Han Chang, 2019, Molecular Diagnosis & Therapy.

the International Association for the Study of Lung Cancer Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

T. Zander, M. Odenthal, Y. Ko, 2015 .

Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004

W. Gradishar, F. Atzori, G. Somlo, 2013, Clinical Cancer Research.

PD01-02: Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study].

G. Curigliano, J. Sohn, W. J. Geese, 2011 .

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

S. Gettinger, F. Shepherd, D. Gerber, 2016 .

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

L. Crinò, N. Rizvi, M. Hellmann, 2016 .

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation.

C. Rudin, M. Hellmann, J. Poirier, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A comprehensive characterization of a group IB intron and its encoded maturase reveals that protein-assisted splicing requires an almost intact intron RNA.

R. Waring, W. Geese, 2001, Journal of molecular biology.

Self-splicing activity of the mitochondrial group-I introns from Aspergillus nidulans and related introns from other species

R. Waring, W. Geese, M. Hur, 1997, Current Genetics.

Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.

J. Neely, M. Sausen, G. Green, 2021 .

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.

K. Harrington, M. Monga, E. Vokes, 2016 .

In vitro analysis of the relationship between endonuclease and maturase activities in the bi-functional group I intron-encoded protein, I-AniI.

R. Waring, William J Geese, Yong K Kwon, 2003, European journal of biochemistry.

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

N. Girard, S. Broderick, K. Kerr, 2017 .

Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer

J. Szustakowski, S. Kirov, Han Chang, 2019, Molecular Diagnosis & Therapy.

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

J. Szustakowski, P. Ascierto, Han Chang, 2018, Cancer cell.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

T. Zander, M. Odenthal, Y. Ko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.